← Leaderboards
Peter J Hotez
George Washington University
$3,993,640
Attributed
$8,682,753
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2008–20$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$8,682,753 · 6
By mechanism
R01$7,063,483 · 2
R56$1,110,931 · 2
R21$454,303 · 1
U54$54,036 · 1
Top collaborators
- Maria Elena Bottazzi7 shared
- Shibo Jiang7 shared
- Jagannadha K Sastry2 shared
- Jeffrey M Bethony1 shared
- Alexander Constantine Loukas1 shared
- Charles R Middaugh1 shared
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesVaccine DevelopmentInfectionResponseBaseVaccine CandidateProteinsPreventRecombinant ProteinsInnovationImmuneImmune ResponseLinkTranslatingImmunogenicityAdjuvantMouse ModelProduct DevelopmentPreparationAluminum SulfateImmunizationLeadLaboratoriesEmergency Situation
Grant awards (17)
Development of a safe and effective RBD-based vaccine against MERS-CoV$549,181
R56 · FY2020 · AI · contact PI
A novel mucosal trichuriasis vaccine for Th2 immune protection.$240,043
R21 · FY2020 · AI · contact PI
A novel mucosal trichuriasis vaccine for Th2 immune protection.$214,260
R21 · FY2019 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,855
R01 · FY2016 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$1,165,726
R01 · FY2015 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$1,134,359
R01 · FY2014 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2014 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$1,085,321
R01 · FY2013 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$3,936
R01 · FY2013 · AI · contact PI
RBD recombinant protein-based SARS vaccine for biodefense$1,501,840
R01 · FY2012 · AI · contact PI
PRODUCT DEVELOPMENT OF A MEMBRANE TETRASPANIN VACCINE AGAINST SCHISTOSOMIASIS$561,750
R56 · FY2011 · AI · contact PI
GWU Training Core$54,036
U54 · FY2008 · AI · contact PI
HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT$268,966
R01 · FY2002 · AI
HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT$118,824
R01 · FY2002 · AI
HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT$325,540
R01 · FY2001 · AI
HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT$231,323
R01 · FY2000 · AI
HOOKWORM LARVAL INFECTIVITY AND DEVELOPMENT$57,857
R01 · FY2000 · AI